Genzyme Obtains European Approval For Renvela

Genzyme has announced that the European Commission has approved Renvela (sevelamer carbonate) for the control of serum phosphorus in patients with chronic kidney disease (CKD).

Renvela is a next-generation version of Renagel (sevelamer hydrochloride), a calcium-free, metal-free, non-absorbed phosphate binder, and has the added benefit of a carbonate buffer.

Markus Ketteler, Professor of Medicine and Clinical Nephrologist, Germany, said: “Hyperphosphatemia is a significant risk factor for cardiovascular disease in patients with CKD, and frequently starts before patients reach dialysis.”

“Renvela is an important addition to the therapeutic options available to nephrologists, and gives them the opportunity to treat hyperphosphatemia earlier,” he added.

Genzyme has been working with regulatory officials worldwide to secure additional approvals for Renvela. The company this quarter launched Renvela in India for CKD patients on dialysis.